Bionor Pharma's Phase II Vacc-4x Data Published in the Lancet Infectious Diseases
11. Februar 2014 09:27 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Feb 11, 2014) - Bionor Pharma ASA (OSE: BIONOR) announces that the results from the randomized, multicenter, double-blinded, placebo-controlled Phase II trial with 135...
Successful Immunization and Safety Documented in Nasal Administration Study of the HIV Vaccine Vacc-4x Together With Endocine
10. Mai 2012 06:47 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - May 10, 2012) - Bionor Pharma (OSLO: BIONOR)
News Summary
Vaccine related immune responses found in HIV patients given Vacc-4x...
Results From Phase IIB Placebo Controlled Study of Bionor Pharma's Vacc-4x Show Excellent Safety Profile, Statistically Significant Viral Load Reduction in Patients With HIV Who Suspend Antiretroviral Therapy
14. September 2011 02:30 ET
|
BionorPharma
BANGKOK, THAILAND--(Marketwire - Sep 14, 2011) - Results from the furthest advanced study of a therapeutic vaccine candidate to treat people living with HIV/AIDS were announced at a news conference...
Bionor Pharma ASA Announces Exploratory Study of Its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination With Leading Cancer Drug
25. August 2011 08:00 ET
|
BionorPharma
OSLO, NORWAY--(Marketwire - Aug 25, 2011) - Bionor Pharma ASA (OSLO: BIONOR) announces plans to conduct an exploratory clinical study using Bionor Pharma's therapeutic HIV-vaccine candidate,...
Researchers Present Findings Today at the XVIII International AIDS Conference, Vienna Austria
22. Juli 2010 06:59 ET
|
BionorPharma
VIENNA, AUSTRIA--(Marketwire - July 22, 2010) - Researchers at Oslo University Hospital and Bionor Pharma's subsidiary, Bionor Immuno AS today presented results from a recently conducted...
Nutri Pharma ASA Adds New CFO to Commercialize Bionor Immuno Pipeline
10. Mai 2010 12:17 ET
|
Nutri Pharma
OSLO, NORWAY and WASHINGTON, DC--(Marketwire - May 10, 2010) - Mr. Rolf Henning Lem has been appointed new CFO of Nutri Pharma ASA (OSLO: NUT). As part of his duties as CFO, Mr. Henning will...
Researchers Find That Vacc-4x Therapeutic Peptide-Based HIV Vaccine Increases CD4 T-Cells in Chronically Infected HIV-1 Patients on Antiretroviral Therapy (ART)
21. Oktober 2009 08:00 ET
|
Bionor Immuno
PARIS--(Marketwire - October 21, 2009) - EMBARGOED FOR RELEASE UNTIL 2:00pm CEST, or 8:00am
USA EST -- Abstract #173886 -- An immunological analysis of a Phase II
clinical trial demonstrated that the...
Bionor Immuno Welcomes Renowned Virologist Robert Redfield, MD to Its Clinical Advisory Board
19. Oktober 2009 10:00 ET
|
Bionor Immuno
BETHESDA, MD and OSLO, NORWAY and PARIS--(Marketwire - October 19, 2009) - Bionor Immuno
announced today at the AIDS Vaccine 2009 conference in Paris, France, that
Robert Redfield, MD, Associate...
Norwegian Research Council Names Bionor Immuno "Most Innovative Company of the Year"
05. Dezember 2008 08:00 ET
|
Bionor Immuno
OSLO, NORWAY and BETHESDA, MD--(Marketwire - December 5, 2008) - Bionor Immuno officials today
accepted the Norwegian Research Council's prestigious "Most Innovative
Company of the Year" award. The...